Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner

Gonadotropin-releasing hormone (GnRH) receptors are expressed in prostate cancer, specifically in the most aggressive stage of the tumor (castration-resistant prostate cancer, CRPC) for which the standard treatment, docetaxel-based chemotherapy, can only improve the median survival time by few month...

Descripción completa

Detalles Bibliográficos
Autores principales: Moretti, Roberta M., Marelli, Marina Montagnani, Taylor, Deanne M., Martini, Paolo G. V., Marzagalli, Monica, Limonta, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983111/
https://www.ncbi.nlm.nih.gov/pubmed/24722580
http://dx.doi.org/10.1371/journal.pone.0093713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983111/
https://www.ncbi.nlm.nih.gov/pubmed/24722580
http://dx.doi.org/10.1371/journal.pone.0093713

Ejemplares similares